Galectin Therapeutics Inc. Company Profile
NASDAQ: GALTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Galectin Therapeutics at a glance
Galectin Therapeutics Inc. (NASDAQ: GALT) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Norcross, GA. Galectin Therapeutics is led by Mr. Joel Lewis CPA and employs about 9 people. At a market capitalization of $365.8 million, it is considered a small-cap company.
Its SEC Central Index Key (CIK) is 0001133416, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Galectin Therapeutics do?
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Business description based on the company's public filings.
Company information
- Legal name
- Galectin Therapeutics Inc.
- Ticker
- NASDAQ: GALT
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Joel Lewis CPA
- Employees
- 9
- Headquarters
- 4960 Peachtree Industrial Boulevard, Norcross, GA, United States
- Phone
- 678 620 3186
- Website
- galectintherapeutics.com
- Market cap
- $365.79M
- SEC CIK
- 0001133416
Companies similar to Galectin Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ARCTArcturus Therapeutics Holdings Inc. | 12.87 | +0.82% | $365.80M | vs GALT |
| IRDOpus Genetics Inc. | 4.46 | +1.13% | $371.05M | vs GALT |
| ENTAEnanta Pharmaceuticals Inc. | 12.10 | -2.18% | $352.42M | vs GALT |
| EBSEmergent BioSolutions Inc. | 6.81 | -3.68% | $349.17M | vs GALT |
| TTRXTurn Therapeutics Inc. | 11.39 | -5.87% | $345.89M | vs GALT |
| RLMDRelmada Therapeutics Inc. | 3.17 | -2.46% | $338.14M | vs GALT |
| AVIRAtea Pharmaceuticals Inc. | 5.16 | +2.89% | $413.46M | vs GALT |
| INDPIndaptus Therapeutics Inc. | 2.37 | +4.87% | $315.78M | vs GALT |